anti-HER2 antibodies (Black Diamond Therapeutics/NYU Grossman School of Medicine)

N/A

Report date: 2025/06/11 10:35:26

Base Information

Drug Nameanti-HER2 antibodies (Black Diamond Therapeutics/NYU Grossman School of Medicine)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionAnticancer protein kinase inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNew York University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBlack Diamond Therapeutics IncNew York University School Of Medicine
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A